- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.10. | Oculis Holding AG: Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development | 231 | GlobeNewswire (Europe) | ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to... ► Artikel lesen | |
| 29.10. | Oculis Holding AG - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 14.10. | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 8 | GlobeNewswire (USA) | ||
| 14.10. | Oculis Holding AG: Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 | 6 | GlobeNewswire (USA) | ||
| 08.10. | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 07.10. | Oculis stock price target raised to $36 from $33 at H.C. Wainwright | 2 | Investing.com | ||
| 06.10. | Oculis Holding AG - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| OCULIS Aktie jetzt für 0€ handeln | |||||
| 06.10. | Oculis takes second eye disease therapy into pivotal trials | 3 | pharmaphorum | ||
| 06.10. | Oculis Holding AG: Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy | 374 | GlobeNewswire (Europe) | Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch... ► Artikel lesen | |
| 26.09. | Oculis Holding AG: Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities | 3 | GlobeNewswire (USA) | ||
| 22.09. | Oculis Holding AG: Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS | 2 | GlobeNewswire (USA) | ||
| 09.09. | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 04.09. | Oculis Holding AG: Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 | 2 | GlobeNewswire (USA) | ||
| 03.09. | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 6 | GlobeNewswire (USA) | ||
| 27.08. | Needham initiates Oculis Holding stock with Buy rating on eye disease portfolio | 7 | Investing.com | ||
| 25.08. | Oculis Holding AG: Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors | 446 | GlobeNewswire (Europe) | Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple... ► Artikel lesen | |
| 22.08. | H.C. Wainwright hebt Kursziel für Oculis Holding auf 33 US-Dollar an | 4 | Investing.com Deutsch | ||
| 22.08. | Stifel reiterates Buy rating on Oculis Holding stock, maintains $35 target | 7 | Investing.com | ||
| 22.08. | Stifel bestätigt Kaufempfehlung für Oculis und Kursziel von 35 US-Dollar | 6 | Investing.com Deutsch | ||
| 21.08. | Oculis Holding AG - 6-K, Report of foreign issuer | 3 | SEC Filings |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,236 | -10,00 % | EQS-News: Evotec SE: In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen | EQS-News: Evotec SE
/ Schlagwort(e): Vereinbarung
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über... ► Artikel lesen | |
| QIAGEN | 37,335 | -0,05 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Aktienrückkauf
QIAGEN N.V.: QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,800 | -1,68 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,630 | +3,30 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering | ZUG, Switzerland, November 5, 2025 - MoonLake Immunotherapeutics (Nasdaq: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,180 | -1,46 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,82 | +0,06 % | Chardan Capital downgrades Avidity Biosciences stock on Novartis acquisition | ||
| RECURSION PHARMACEUTICALS | 4,630 | +0,22 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| MBX BIOSCIENCES | 25,570 | +3,40 % | MBX Biosciences, Inc.: MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Reported positive topline results from the Phase 2 Avail trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross... ► Artikel lesen | |
| BIONTECH | 89,05 | -0,22 % | Biontech öffnet seine Bücher | MAINZ (dpa-AFX) - Nach der Verkündung mehrerer größerer Deals wird das Pharmaunternehmen Biontech an diesem Montag frische Geschäftszahlen vorlegen. Äußern dürften sich die Mainzer bei der Vorlage... ► Artikel lesen | |
| DISC MEDICINE | 83,85 | -3,62 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,520 | +3,49 % | ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales | ||
| KINIKSA PHARMACEUTICALS | 38,370 | -0,67 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,350 | +0,80 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 8,200 | -2,61 % | Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 168,41 | -2,11 % | Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline |
Das Unternehmen OCULIS HOLDING AG kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 17,200 Euro und damit +6,83 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OCULIS HOLDING AG finden Sie auf Wallstreet Online.